 | Monter d'un niveau |
Orlando, L., Maiello, E., Orditura, M., Diana, A., Antoniol, G., Morritti, M. G., Aieta, M., Ciccarese, M., Pisconti, S., Bordonaro, R., Russo, A., Febbraro, A., Schiavone, P., Quaranta, A., Caliolo, C., Loparco, D., Cinefra, M., Colucci, G., & Cinieri, S. (2024). Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. The Breast, 75, 103725-103725. Lien externe
Iovino, F., Diana, A., Carlino, F., Ferraraccio, F., Antoniol, G., Fisone, F., Perrone, A., Zito Marino, F., Panarese, I., Tathode, M. S., Caraglia, M., Gatta, G., Ruggiero, R., Parisi, S., De Vita, F., Ciardiello, F., Docimo, L., & Orditura, M. (2022). Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis. Journal of Clinical Medicine, 11(23), 6987 (15 pages). Lien externe
Carlino, F., Diana, A., Ventriglia, A., Piccolo, A., Mocerino, C., Riccardi, F., Bilancia, D., Giotta, F., Antoniol, G., Famiglietti, V., Feliciano, S., Cangiano, R., Lobianco, L., Pellegrino, B., De Vita, F., Ciardiello, F., & Orditura, M. (2022). HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. Cancers, 14(20), 4981 (11 pages). Lien externe
Diana, A., Carlino, F., Buono, G., Antoniol, G., Famiglietti, V., De Angelis, C., Carrano, S., Piccolo, A., De Vita, F., Ciardiello, F., Daniele, B., Arpino, G., & Orditura, M. (2022). Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. Frontiers in Oncology, 12. Lien externe
